Clinical trial
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
NCT00429312 · Jennerex Biotherapeutics, Industry · Completed
Key facts
| NCT number | NCT00429312 |
|---|---|
| Title | A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma |
| Official title | A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma |
| Lead sponsor | Jennerex Biotherapeutics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | JX-594 |
| Enrollment | 10 |
| Start date | Mar 1, 2007 |
| Primary completion | Feb 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Jan 31, 2007 |
| Last update posted | Jan 15, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: